Wang Jian'an, M.D., Ph.D., F.A.C.C.

Position:Head of SAHZU, Chair of Heart Center, Editor-in-Chief, JACC: Asia


Academic Rank:Professor, Chief Physician

Dr. Jian'an Wang currently serves as the head of the Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), as well as the Professor and Associate Dean of Zhejiang University School of Medicine. Under his leadership for over 10 years as a hospital president, SAHZU has been moved up to a top-ranking hospital in China. 

As an experienced interventional cardiologist, he spearheaded the efforts in establishing and developing one of the biggest valvular heart disease programs in Asia and was invited to proctor TAVR procedure in Asia, Europe and South America. He has developed several CFDA approved innovative devices for valvular interventions in collaboration with engineers, CV colleagues and manufacturers. His bench side research focuses on improving the efficacy of stem cell implantation in infarcted myocardium. He is a veteran principal investigator of clinical trials including big sample international multicenter RCT studies. His FLAVOUR study with counterparts in South Korea was published on NEJM and selected as late breaking trial of ACC 2022. 

Deeply engaged in activities of medical societies, he currently serves as the Vice Chairman of Chinese Cardiology Society and the Co-Chairman of Congenital Structural Interventions headquartered in Frankfurt, Germany. He is the inaugural Editor-in-Chief of JACC: Asia and World Journal of Emergency Medicine as well. In view of his remarkable contribution to CV, he was appointed as member of Chinese Academy of Sciences in 2023.


Clinical / Research Interests


Coronary heart disease

Myocardial infarction

Heart failure

Valve disease interventional therapy

Professional Highlights

Ho Leung Ho Lee Foundation Award, 2018

Zhejiang Science and Technology Significant Contribution Award, 2016

Zhejiang Scientific and Technological Progress Award, First Prize, 2013

The National Bethune Medal, 2012

State Scientific and Technological Progress Award, Second Prize, 2012

Zhejiang Scientific and Technological Progress Award, First Prize, 2008

Zhejiang Scientific and Technological Progress Award, Second Prize, 2005

Science and Technology Progress, Education Department of Zhejiang Province, Second Prize, 2005

Chinese Medical Science and Technology Award, Third Prize, 2004

Zhejiang Scientific and Technological Progress Award, Third Prize, 2002

Zhejiang Scientific and Technological Progress Award, Second Prize, 2001 

Professional Appointments

Member, Chinese Academy of Sciences

Editor-in-Chief, JACC: Asia

Co-director, European CSI

Vice Chairman, Asian Society of Cardiology

Fellow, American College of Cardiology

Vice President, Chinese Society of Cardiology

Chairman, Zhejiang Provincial Cardiology Association

Director, Zhejiang Provincial Key Laboratory of Cardiology

Director, Zhejiang University Cardiovascular Institute

Education Experience

Advanced Training in Interventional Cardiology, Loma Linda Medical Center, USA

Advanced Training in Cardiology, Queen Mary Hospital, Hong Kong

Research Summary

Development of transcatheter aortic valve interventional devices and valve repair devices with independent intellectual property rights.

Innovation on theory and technique of transcatheter aortic valve replacement (TAVR), especially supra-annular structure based sizing strategy (Hangzhou Solution), which has significantly lowerd TAVR mortality and complication rates. This strategy now is widely accepted worldwide among cardiologists.

Proposition of important theories of cardiac function reconstruction after myocardial infarction, including the theory and scheme of hypoxic preconditioning of mesenchymal stem cells to improve cardiac function, and the discovery of important paracrine substances and molecular mechanisms.

Longest cycle of non-human primate research in the field of cardiac function reconstruction. 


Selected publications: 

Koo BK#, Hu X#, Kang J#, etc, Tahk SJ*,Wang J*; FLAVOUR Investigators. Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. N Engl J Med. 2022 Sep 1;387(9):779-789. Doi:10.1056/NEJMoa2201546.

Ye F#, Wang X#, Wu S, Ma S, Zhang Y, Liu G, Liu K, Yang Z, Pang X, Xue L, Lu S, Zhong M, Li J, Yu H, Lou D, Cui D, Xie X*, Wang J*; FIRST Investigators. Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure. J Am Coll Cardiol(JACC). 2022 Aug 9;80(6):584-594. Doi:10.1016/j.jacc.2022.05.027.

Li Q#, Xu Y#, Lv K#, Wang Y, Zhong Z, Xiao C, Zhu K, Ni C, Wang K, Kong M, Li X, Fan Y, Zhang F, Chen Q, Li Y, Li Q, Liu C, Zhu J, Zhong S, Wang J, Chen Y, Zhao J, Zhu D, Wu R, Chen J, Zhu W, Yu H, Ardehali R, Zhang JJ*, Wang J*, Hu X*. Small extracellular vesicles containing miR-486-5p promote angiogenesis after myocardial infarction in mice and nonhuman primates. Sci Transl Med. 2021 Mar 10;13(584):eabb0202. Doi:10.1126/scitranslmed.abb0202.

Rong J#, Tao X#, Lin Y, Zheng H, Ning L, Lu HS, Daugherty A, Shi P, Mullick AE, Chen S, Zhang Z*, Xu Y*, Wang J*. Loss of Hepatic Angiotensinogen Attenuates Sepsis-Induced Myocardial Dysfunction. Circulation Res. 2021 Aug 20;129(5):547-564. Doi:10.1161/CIRCRESAHA.120.318075.

Wu R#, Hu W#, Chen H, Wang Y, Li Q, Xiao C, Fan L, Zhong Z, Chen X, Lv K, Zhong S, Shi Y, Chen J, Zhu W, Zhang J, Hu X*, Wang J*. A Novel Human Long Noncoding RNA SCDAL Promotes Angiogenesis through SNF5-Mediated GDF6 Expression. Adv Sci (Weinh). 2021 Sep;8(18). Doi:10.1002/advs.202004629.

Fan J, Fang X, Liu C, Zhu G, Hou CR, Jiang J, Lin X, Wang L, He Y, Zhu Q, Ng S, Chen Z, Hu H, Liu X*, Wang J*, Leon MB. Brain Injury After Transcatheter Replacement of Bicuspid Versus Tricuspid Aortic Valves. J Am Coll Cardiol(JACC). 2020 Dec 1;76(22):2579-2590. Doi:10.1016/j.jacc.2020.09.605.

Zhu K#, Wu Q#, Ni C#, Zhang P, Zhong Z, Wu Y, Wang Y, Xu Y, Kong M, Cheng H, Tao Z, Yang Q, Liang H, Jiang Y, Li Q, Zhao J, Huang J, Zhang F, Chen Q, Li Y, Chen J, Zhu W, Yu H, Zhang J, Yang HT*, Hu X*, Wang J*. Lack of Remuscularization Following Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitor Cells in Infarcted Nonhuman Primates. Circulation Res. 2018 Mar 30;122(7):958-969. Doi:10.1161/CIRCRESAHA.117.311578.

Nan J#, Hu H#, Sun Y#, Zhu L, Wang Y, Zhong Z, Zhao J, Zhang N, Wang Y, Wang Y, Ye J, Zhang L, Hu X, Zhu W*, Wang J*. TNFR2 Stimulation Promotes Mitochondrial Fusion via Stat3- and NF-kB-Dependent Activation of OPA1 Expression. Circulation Res. 2017 Aug 4;121(4):392-410.

Hu X#, Xu Y#, Zhong Z, Wu Y, Zhao J, Wang Y, Cheng H, Kong M, Zhang F, Chen Q, Sun J, Li Q, Jin J, Li Q, Chen L, Wang C, Zhan H, Fan Y, Yang Q, Yu L, Wu R, Liang J, Zhu J, Wang Y, Jin Y, Lin Y, Yang F, Jia L, Zhu W, Chen J, Yu H, Zhang J*, Wang J*. A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Nonhuman Primates: Paracrine Activity Without Remuscularization. Circulation Research. 2016 Mar 18;118(6):970-83. Doi:10.1161/CIRCRESAHA.115.307516.

Hu H#, Nan J#, Sun Y#, Zhu D, Xiao C, Wang Y, Zhu L, Wu Y, Zhao J, Wu R, Chen J, Yu H, Hu X, Zhu W*, Wang J*. Electron leak from NDUFA13 within mitochondrial complex I attenuates ischemia-referfusion injury via dimerized STAT3. PNAS,2017;114(45):11908-11913.

Current Program

Expansion of human pluripotent stem cell differentiation cardiac lineage and its efficacy and safety after transplantation. Funding Source: National Key Research and Development Program.

Study on the mechanism of GRIM19 moderately down-regulating stem cell survival through mitochondrial autophagy. Funding Source: National Natural Science Foundation of China.

Research on new techniques for the treatment of heart valve disease. Funding Source: Key Research and Development Project of Zhejiang Province.

The effect and mechanism of angiotensinogen on atherosclerosis. Funding Source: National Natural Science Foundation of China. 

Research on key issues of human embryonic stem cell-derived cells in the treatment of heart failure after myocardial infarction. Funding Source: National Program on Key Basic Research Project.

Construction of technology platform for clinical evaluation and research of new drugs for cardiovascular diseases. Funding Source: National Science and Technology Major Project.

Standardized treatment and key technologies for disasters and severe trauma. Funding Source: Health Commission of China.

For more publications:

Find People

Search by Family Name

Find A Department

Search by Departments